NCT03912233: A reported trial by Vertex Pharmaceuticals Incorporated
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03912233 |
|---|---|
| Title | A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 30, 2019 |
| Completion date | Dec. 10, 2019 |
| Required reporting date | Dec. 10, 2022, midnight |
| Actual reporting date | Oct. 13, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |